More problems for BioNTech & Roche’s neoantigen shot
Autogene cevumeran goes on hold in adjuvant bladder cancer.
Arvinas leader departs under a Pfizer-shaped cloud
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
Early validation for in vivo Car-T
ESO-T01 delivers its first four multiple myeloma case reports.
Concentra picks up a new Cargo
The Tang Capital Partners vehicle has already acquired IGM, Elevation and Kronos.
Chia Tai broadens its biparatopic breast cancer approach
The company, apparently unbothered by Enhertu, is starting a new HER2 x HER2 phase 3.
Safety remains the key metric for Cogent
Bezuclastinib's registrational trial meets predefined success criteria, with a big spotlight on toxicity.
Licensing analysis: big deals bolster biotech
PD-(L)1 x VEGF bispecifics prove a big draw.
